美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · MLTX近 30 天 1 則 · 第 1 / 1 頁
- MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
- MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
- MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
- Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
- SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
- MoonLake Immunotherapeutics' CFO Sells 39K Shares
- MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa
- How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering
- Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
- MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development
- MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
- MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?
- MoonLake Immunotherapeutics Announces Proposed Public Offering
- Why Is MLTX Stock Rallying Nearly 20% Overnight?
- MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
- MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts
- Why Did MLTX Stock Rise After-Hours Today?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。